87 related articles for article (PubMed ID: 27290654)
1. Timing determines dexamethasone and rituximab induced synergistic cell death.
Adem J; Eray M; Eeva J; Nuutinen U; Pelkonen J
Mol Immunol; 2016 Jul; 75():200-2. PubMed ID: 27290654
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-induced early and late signaling have opposite effects on dexamethasone-induced apoptosis in human follicular lymphoma cells.
Adem J; Ropponen A; Eeva J; Eray M; Pelkonen J; Nuutinen U
Leuk Lymphoma; 2015; 56(8):2448-57. PubMed ID: 25563557
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
[TBL] [Abstract][Full Text] [Related]
4. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
[TBL] [Abstract][Full Text] [Related]
5. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
Nahimana A; Aubry D; Breton CS; Majjigapu SR; Sordat B; Vogel P; Duchosal MA
Leuk Lymphoma; 2014 Sep; 55(9):2141-50. PubMed ID: 24283753
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
7. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
8. Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles.
Popov J; Gilabert-Oriol R; Bally MB
Eur J Pharm Biopharm; 2017 Aug; 117():256-269. PubMed ID: 28450189
[TBL] [Abstract][Full Text] [Related]
9. Differential Expression of Bcl-2 Family Proteins Determines the Sensitivity of Human Follicular Lymphoma Cells to Dexamethasone-mediated and Anti-BCR-mediated Apoptosis.
Adem J; Ropponen A; Eeva J; Eray M; Nuutinen U; Pelkonen J
J Immunother; 2016 Jan; 39(1):8-14. PubMed ID: 26641257
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
An J; Sun Y; Fisher M; Rettig MB
Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
[TBL] [Abstract][Full Text] [Related]
11. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Qian Z; Zhang L; Cai Z; Sun L; Wang H; Yi Q; Wang M
Leuk Res; 2011 Mar; 35(3):380-6. PubMed ID: 21047686
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
[TBL] [Abstract][Full Text] [Related]
15. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
16. Control of Atm-/- thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone.
Kuang X; Yan M; Liu N; Scofield VL; Qiang W; Cahill J; Lynn WS; Wong PK
Cancer Chemother Pharmacol; 2005 Mar; 55(3):203-12. PubMed ID: 15570424
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
18. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
Smolewski P; Robak T
Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
Neri P; Yasui H; Hideshima T; Tassone P; Raje N; Catley LP; Ishitsuka K; Blotta S; Kiziltepe T; Ocio EM; Fulciniti M; Kanekal S; Elliott GT; Munshi NC; Anderson KC
Br J Haematol; 2006 Jul; 134(1):37-44. PubMed ID: 16803565
[TBL] [Abstract][Full Text] [Related]
20. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
Miyake Y; Okoshi Y; Machino T; Chiba S
Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
